TG Therapeutics, Inc. (TGTX) Institutional Ownership & Insider Trading

426 institutions reported holding TG Therapeutics, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 2 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

TGTXTG Therapeutics, Inc.Follow TGTX — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 8.3B
P/E TTM: 19.7
Dividend yield: —
52-week: —
Next earnings: 9 Nov, in 16 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

426 institutions held 72.6% of the shares. Across filers that reported both quarters, shares held changed +5.5%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	426	111	+5.5%	136	87	110	27
Mar 26	359	105	+3.0%	125	54	90	43
Dec 25	346	103	+3.9%	115	41	98	43
Sep 25	345	99	-3.0%	92	37	118	39
Jun 25	350	101	+2.4%	127	38	98	55
Mar 25	367	98	+2.9%	103	71	106	31
Dec 24	323	97	-5.1%	85	61	77	50
Sep 24	302	101	-4.4%	85	84	67	36

TG Therapeutics, Inc. — questions

Who owns TG Therapeutics, Inc. stock?: 426 institutions reported TG Therapeutics, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (14.4%), VANGUARD PORTFOLIO MANAGEMENT LLC (5.2%), STATE STREET CORP (5.1%).
Are TG Therapeutics, Inc. insiders buying or selling?: 2 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from TG Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.